Full history for every metric is available with a Kvantra account
Tyme Technologies, Inc. (TYME)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -26 | -25 | |||||
| Net profit | $m | -15 | -19 | -33 | -22 | -29 | -22 | -24 |
| EPS reported | $ | -0.13 | -0.14 | |||||
| Operating cashflow per share | $ | -0.12 | -0.12 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.12 | -0.12 | |||||
| Free cash flow | $m | -21 | -20 | |||||
| Net debt | $m | -74 | -77 | |||||
| Book value equity | $m | 80 | 74 | |||||
| Book value per share | $ | 0.47 | 0.43 | |||||
| Number of shares | m | 172.21 | 172.21 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.75 | 0.72 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -2.84 | -2.65 | |||||
| EV/EBITDA LTM | x | -2.16 | 1.18 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -35.95% | -40.50% | |||||
| FCF Yield | % | -35.24% | -37.78% | |||||
| Quality | ||||||||
| ROE | % | -27.06% | -23.83% | |||||
| ROIC | % | -29.01% | -29.01% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -569.02 | -763.17 | |||||
| Net Debt/EBITDA | x | 0.63 | 0.63 | |||||
| EBIT/Net interest | x | -363.21 | -363.21 | |||||
| Net debt/market cap | % | -123.30% | -144.11% | |||||
| Net debt/Equity | x | -0.93 | -1.04 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Tyme Technologies, Inc. is a biopharmaceutical firm dedicated to developing cancer metabolism-based therapies (CMBTs) within the United States. Its flagship therapeutic candidate, SM-88, is currently undergoing Phase II/III clinical evaluation across 15 distinct cancer types, including but not limited to pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company's pipeline also includes TYME-19, an orally administered synthetic bile acid derivative in preclinical stages for combating SARS-CoV-2 infections, and TYME-18, another preclinical CMBT compound designed to treat tumors that are inoperable. Tyme Technologies maintains research partnerships, notably with the Mayo Clinic for comprehensive analysis of SM-88's impact on pancreatic cancer cell gene expression, epigenetics, and metabolic changes, and with a research investigator at Georgetown University to study SM-88's effects in breast cancer. Founded in 2011 as Global Group Enterprises Corp. and headquartered in Bedminster, New Jersey, Tyme Technologies, Inc. has been operating as a subsidiary of Syros Pharmaceuticals, Inc. since September 16, 2022.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Tyme Technologies, Inc. (TYME)
Tyme Technologies, Inc. is a biopharmaceutical firm dedicated to developing cancer metabolism-based therapies (CMBTs) within the United States. Its flagship therapeutic candidate, SM-88, is currently undergoing Phase II/III clinical evaluation across 15 distinct cancer types, including but not limited to pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company's pipeline also includes TYME-19, an orally administered synthetic bile acid derivative in preclinical stages for combating SARS-CoV-2 infections, and TYME-18, another preclinical CMBT compound designed to treat tumors that are inoperable. Tyme Technologies maintains research partnerships, notably with the Mayo Clinic for comprehensive analysis of SM-88's impact on pancreatic cancer cell gene expression, epigenetics, and metabolic changes, and with a research investigator at Georgetown University to study SM-88's effects in breast cancer. Founded in 2011 as Global Group Enterprises Corp. and headquartered in Bedminster, New Jersey, Tyme Technologies, Inc. has been operating as a subsidiary of Syros Pharmaceuticals, Inc. since September 16, 2022.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free